TCL6 had been demonstrated to be a potential tumor suppressor in breast cancer (Zhang et al., 2020), hepatocellular carcinoma (Luo et al., 2020), renal cell carcinoma (Yang et al., 2018; Kulkarni et al., 2021), and B-cell acute lymphoblastic leukemia (Cuadros et al., 2019). Here, TCL6 is linked to renal cell carcinoma.